中源协和细胞基因工程股份有限公司 非经营性资金占用及其他关联资金往来情况的 专项审计说明 :您可使用手机"扫一扫"来进入"提供关于解行业绩一流管平台《http://sec.nl._ 进行在线 _您可使用手机_"扫一扫"来进入"提案会计师行业线—监管平台《http://sec.nl._ 进行在线 _ 【 天 1建 | Ж | | --- | 一、非经营性资金占用及其他关联资金往来情况的专项 审计说明………………………………………………………………………………………第 1—2 页 二、非经营性资金占用及其他关联资金往来情况汇总表 ………… 第 3-4页 11 非经营性资金占用及其他关联资金往来情况的 专项审计说明 天健审〔2025〕771号 中源协和细胞基因工程股份有限公司全体股东: 我们接受委托,审计了中源协和细胞基因工程股份有限公司(以下简称中源 协和公司)2024年度财务报表,包括2024年12月31日的合并及母公司资产负 债表,2024年度的合并及母公司利润表、合并及母公司现金流量表、合并及母 公司所有者权益变动表,以及财务报表附注,并出具了审计报告。在此基础上, 我们审计了后附的中源协和公司管理层编制的 ...

中源协和细胞基因工程股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我 们审计了中源协和细胞基因工程股份有限公司（以下简称中源协和公司）2024 年 12 月 31 日的财务报告内部控制的有效性。 目 录 一、内部控制审计报告…………………………………………第 1—2 页 内部控制审计报告 天健审〔2025〕7769 号 一、企业对内部控制的责任 按照《企业内部控制基本规范》《企业内部控制应用指引》以及《企业内部 控制评价指引》的规定，建立健全和有效实施内部控制，并评价其有效性是中源 协和公司董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的有效性发表 审计意见，并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。此外，由于 情况的变化可能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低， 根据内部控制审计结果推测未来内部控制的有效性具有一定风险。 四、财务报告内部控制审计意见 我们认为，中源协和公司于 2024 年 12 月 31 日按 ...

前十大流通股东累计持有： 14465.33万股，累计占流通股比： 30.91%，较上期变化： -455.98万股。 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.2200 | 0.2300 | -4.35 | 0.2400 | | 每股净资产（元） | 7.68 | 7.87 | -2.41 | 7.6 | | 每股公积金(元) | 7.21 | 7.22 | -0.14 | 7.23 | | 每股未分配利润(元) | -0.46 | -0.68 | 32.35 | -0.91 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 15.85 | 15.9 | -0.31 | 15.55 | | 净利润(亿元) | 1 | 1.06 | -5.66 | 1.13 | | 净资产收益率(%) | 2.77 | 2.94 | -5.78 | 3.23 | 数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情 ...

Financial Performance - Revenue for the first quarter was CNY 350,790,044.48, a decrease of 11.86% compared to the same period last year[4] - Net profit attributable to shareholders decreased by 30.18% to CNY 28,030,417.80[4] - Basic and diluted earnings per share both decreased by 33.33% to CNY 0.06[4] - Total operating revenue for Q1 2025 was CNY 350,790,044.48, a decrease of 11.85% compared to CNY 397,981,195.71 in Q1 2024[17] - Net profit for Q1 2025 was CNY 25,554,539.25, representing a decline of 38.39% from CNY 41,500,411.38 in Q1 2024[18] - The total profit for Q1 2025 was CNY 36,274,765.27, a decrease of 36.14% from CNY 56,753,233.47 in Q1 2024[17] - The total comprehensive income for Q1 2025 was CNY 23,668,355.70, down from CNY 34,730,937.04 in Q1 2024[18] Cash Flow and Operating Activities - Net cash flow from operating activities increased by 116.56% to CNY 46,398,618.68, primarily due to reduced cash payments for goods and services[6] - The net cash flow from operating activities for Q1 2025 was CNY 46,398,618.68, an increase of 117.79% compared to CNY 21,424,807.24 in Q1 2024[20] - The company reported a net cash increase of CNY 26,421,366.46 in Q1 2025, compared to a decrease of CNY 61,147,234.13 in Q1 2024[21] Assets and Liabilities - Total assets at the end of the reporting period were CNY 5,248,825,312.86, showing no significant change from the previous year[5] - The company's total liabilities decreased from RMB 1,589,880,909.12 to RMB 1,566,091,503.50, indicating a reduction of approximately 1.96%[14] - Cash and cash equivalents rose to RMB 1,551,411,991.22 from RMB 1,524,990,910.90, marking an increase of approximately 1.73%[12] - Accounts receivable slightly decreased from RMB 609,136,583.85 to RMB 605,065,698.13, a decline of about 0.34%[12] - Inventory increased from RMB 232,194,124.88 to RMB 236,839,792.84, representing a growth of approximately 2.76%[12] Shareholder Information - The company reported a total of 34,948 common shareholders at the end of the reporting period[8] - The largest shareholder, Tianjin Deyuan Health Management Co., Ltd., holds 12.14% of the shares[8] - Shareholders' equity attributable to shareholders increased by 0.73% to CNY 3,621,231,799.18[5] - The weighted average return on equity decreased by 0.31 percentage points to 0.78%[5] Research and Development - Research and development expenses for Q1 2025 were CNY 38,582,620.51, a decrease of 12.00% from CNY 43,793,779.30 in Q1 2024[17] Foreign Exchange and Other Income - The company experienced a foreign exchange loss of CNY 1,339,995.40 in Q1 2025, compared to a gain of CNY 1,793,398.34 in Q1 2024[21] - The company received government subsidies amounting to CNY 232,527.68 during the reporting period[6] Pledges and Financing - The company has pledged 32,723,260 shares to Shenzhen Jiadao Success Investment Enterprise, with a pledge expiration date of April 20, 2027[10] - The company has not reported any significant changes in the participation of major shareholders in margin financing and securities lending activities[10]

Financial Performance - The audited net profit for the parent company in 2024 is -12.76 million RMB, with cumulative undistributed profits amounting to -306 million RMB as of December 31, 2024[6]. - The consolidated undistributed profits stand at -217 million RMB, indicating that the company is currently not in a position to distribute dividends[6]. - The net profit attributable to shareholders of the listed company is 100.35 million RMB, reflecting a decline of 5.73% year-over-year[23]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is 120.26 million RMB, down 5.09% from the previous year[23]. - Cash flow from operating activities for 2024 is 285.19 million RMB, a decrease of 4.62% compared to 2023[23]. - The company reported a net profit of CNY 48,327,768.55 in the third quarter of 2024, but a loss of CNY 33,160,745.14 in the fourth quarter[27]. - The company reported a significant increase in financial expenses by 40.11%, primarily due to reduced interest income and increased exchange losses[93]. - The company’s audited net profit for 2023 was -80.69 million CNY, with cumulative undistributed profits at -293 million CNY as of December 31, 2023, indicating no dividend distribution for the year[187]. - The company plans to repurchase shares with a cash amount of 200 million CNY, which represents 199.32% of the net profit for the year[189]. Revenue and Growth - Operating revenue for 2024 is 1.59 billion RMB, a slight decrease of 0.27% compared to 2023[23]. - Total revenue for the first quarter of 2024 was CNY 397,981,195.71, with net profit attributable to shareholders at CNY 40,149,488.80[27]. - The revenue from testing reagents increased by 7.28% to 915.58 million RMB, while the revenue from research reagents decreased by 5.84% to 194.79 million RMB[92]. - The direct sales model generated 1.25 billion RMB in revenue, with a slight increase of 2.34%[98]. - The company achieved operating revenue of 1.585 billion RMB, a decrease of 0.27% compared to the previous year[91]. Assets and Liabilities - Total assets as of the end of 2024 are 5.25 billion RMB, down 3.00% from the end of 2023[24]. - Net assets attributable to shareholders of the listed company are 3.60 billion RMB, a decrease of 2.42% from the previous year[24]. - Long-term borrowings decreased by 100% compared to the beginning of the period, primarily due to repayment of loans during the reporting period[110]. - Non-current liabilities due within one year increased by 47.58% compared to the beginning of the period, mainly due to an increase in lease liabilities[110]. Research and Development - R&D investment totaled approximately 19.52 million yuan in 2024, accounting for 12.31% of total revenue, reflecting the company's commitment to innovation[40]. - The company is focusing on the development of innovative cell and gene therapies, supported by favorable government policies and market conditions[63]. - The company is actively promoting the research and development of cell drugs and clinical projects for stem cells, aiming to establish a complete pathway from prospective research to clinical application[78]. - The company has completed 33 out of 66 ongoing research projects related to stem cell research and product development[107]. - The company is focusing on expanding its business network through partnerships with influential insurance and health management companies to support rapid growth in cell storage services[131]. Market and Industry Trends - The biopharmaceutical industry is experiencing increased governmental support, with policies aimed at accelerating the development of innovative drugs and therapies[52]. - The adult stem cell storage market is expanding, driven by an increase in the elderly population from 126 million in 2000 to 297 million in 2023, representing a rise from 10.2% to 21.1% of the total population[130]. - The immune cell storage market in China is projected to grow from approximately RMB 200 million in 2016 to RMB 2.1 billion in 2023, with a compound annual growth rate (CAGR) of 44.4% from 2016 to 2023, and an expected CAGR of 21.7% from 2023 to 2032, reaching RMB 12.2 billion by 2032[131]. - The policy environment for stem cell therapy has been significantly improved, with a comprehensive regulatory framework established since 2015 to promote clinical research and product development[127]. Corporate Governance - The company has a clear plan for future financial budgeting and performance guidance for the upcoming fiscal year[159]. - The company has established specialized committees, including the Audit Committee and the Compensation and Assessment Committee, to oversee various governance aspects[177]. - The board approved the 2024 financial budget report and the first quarter report of 2024[174]. - The company has a structured approach to managing executive compensation, ensuring transparency and fairness[162]. - The company emphasizes the importance of good corporate governance for sustainable development[159]. Strategic Initiatives - The company aims to enhance its strategic layout and accelerate R&D transformation to strengthen brand value and competitiveness in the cell therapy and in vitro diagnostics sectors[34]. - The company plans to enhance production processes by introducing automated, large-scale, closed washing equipment to improve cell harvesting efficiency and achieve serum-free culture across all processes[141]. - The company intends to build a comprehensive family health management ecosystem, launching adult immune cell storage plans for existing newborn families and integrating health monitoring and risk assessment services[144]. - The company is focusing on building a comprehensive ecosystem for cell services by collaborating with influential insurance and health management companies[43]. Risks and Challenges - The company faces industry policy risks due to potential future regulations in stem cell and gene-related fields, which may impact operations[145]. - The company acknowledges talent retention risks as it expands, emphasizing the need for a stable core team and effective incentive mechanisms to prevent talent loss[146]. - The company recognizes R&D and technology risks, particularly in maintaining technological leadership in cell preservation and clinical applications amid increasing global competition[147]. - The company is aware of market risks related to declining newborn birth rates, which may affect the growth of its newborn storage business and adult cell storage market expansion[149]. Certifications and Compliance - The company has received ISO9001, ISO14001, and ISO45001 certifications, marking a significant upgrade in quality management, environmental protection, and employee health and safety standards[46]. - The company has established a quality management department and a product transformation and production department to enhance quality control and operational independence[47]. - The company has implemented a traceability system for stem cell therapy products, ensuring full-chain traceability from source to end[47]. - The internal control audit report issued by Tianjian Accounting Firm received a standard unqualified opinion[198].

中源协和细胞基因工程股份有限公司 2024 年度独立董事述职报告 作为中源协和细胞基因工程股份有限公司（以下简称"公司"）独立董事， 2024年度本人严格按照《公司法》、《上市公司治理准则》、《上市公司独立董 事管理办法》、《上海证券交易所股票上市规则》、《上海证券交易所上市公司 自律监管指引第1号——规范运作》等法律、法规及规范性文件和《公司章程》、 《独立董事工作制度》、《独立董事年报工作制度》的规定和要求，认真行使了 独立董事的权利，忠实勤勉地履行了独立董事的职责，充分发挥独立董事的独立 作用，切实维护了公司和股东尤其是中小股东的合法权益。 （一）出席董事会、股东大会会议的情况 2024年度，本人出席董事会、股东大会会议的情况如下： | | | | | | 出席董事会情况 | | | 出席股东大 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 独立董 | | | | | | | | 会情况 | | 事姓名 | 本年应参 | 亲自出 | 以 | 通 讯 | 委托 | 缺席 | 是否连续两 | 出席股东大 | | | 加董事会 | 席次 ...

独立性的相关要求。 中源协和细胞基因工程股份有限公司董事会 关于独立董事独立性情况的专项意见 根据《上市公司独立董事管理办法》、《上海证券交易所股票上市规则》、《上 海证券交易所上市公司自律监管指引第 1 号——规范运作》等要求，中源协和 细胞基因工程股份有限公司（以下简称"公司"）董事会，就公司在任独立董事 裴端卿、侯欣一、罗明生的独立性情况进行评估并出具如下专项意见： 经核查独立董事的任职经历及其签署的自查情况表等文件，上述人员未在公 司担任除独立董事以外的任何职务，也未在公司主要股东公司担任任何职务，与 公司以及主要股东之间不存在利害关系或其他可能妨碍其进行独立客观判断的 关系，不存在影响独立董事独立性的情况，符合《上市公司独立董事管理办法》、 《上海证券交易所上市公司自律监管指引第 1 号——规范运作》中对独立董事 二○二五年四月二十三日 （以下无正文） 本页无正文，为《中源协和细胞基因工程股份有限公司董事会关于独立董事独立 性情况的专项意见》之签署页 龚虹嘉 WANG HONGQI 王 勇 （王洪琦） 吴 珊 李 旭 李海滨 裴端卿 侯欣一 罗明生 ...

中源协和细胞基因工程股份有限公司 2024 年度独立董事述职报告 作为中源协和细胞基因工程股份有限公司（以下简称"公司"）独立董事， 2024年度本人严格按照《公司法》、《上市公司治理准则》、《上市公司独立董 事管理办法》、《上海证券交易所股票上市规则》、《上海证券交易所上市公司 自律监管指引第1号——规范运作》等法律、法规及规范性文件和《公司章程》、 《独立董事工作制度》、《独立董事年报工作制度》的规定和要求，认真行使了 独立董事的权利，忠实勤勉地履行了独立董事的职责，充分发挥独立董事的独立 作用，切实维护了公司和股东尤其是中小股东的合法权益。 现将2024年度履职情况报告如下： 一、独立董事的基本情况 侯欣一，男，64 岁，法学博士。 现任公司独立董事、山东大学特聘教授、凯莱英医药集团（天津）股份有限 公司独立董事、天津卓朗信息科技股份有限公司独立董事、最高人民检察院特约 检察员。 曾任天津财经大学法学教授和博士生导师、南开大学法学院教授和博士生导 师、中国法律史学会执行会长、中国农工民主党天津市委员会副主委、全国政协 委员、天津市房地产发展(集团)股份有限公司独立董事、天津鑫茂科技股份有限 公司独立董事 ...

中源协和细胞基因工程股份有限公司 2024 年度独立董事述职报告 作为中源协和细胞基因工程股份有限公司（以下简称"公司"）独立董事， 2024年度本人严格按照《公司法》、《上市公司治理准则》、《上市公司独立董 事管理办法》、《上海证券交易所股票上市规则》、《上海证券交易所上市公司 自律监管指引第1号——规范运作》等法律、法规及规范性文件和《公司章程》、 《独立董事工作制度》、《独立董事年报工作制度》的规定和要求，认真行使了 独立董事的权利，忠实勤勉地履行了独立董事的职责，充分发挥独立董事的独立 作用，切实维护了公司和股东尤其是中小股东的合法权益。 现将2024年度履职情况报告如下： 一、独立董事的基本情况 罗明生，男，59 岁，会计本科，注册会计师、注册税务师。 现任公司独立董事、惠生国际控股有限公司独立董事、湖南金基陈设艺术有 限公司执行董事、总经理、湖南简之文化发展有限公司执行董事、总经理。 曾任华寅会计师事务所高级合伙人、湖南希尔得拍卖有限公司董事长、创智 和宇信息技术股份有限公司董事、湖南创智和宇企业管理有限公司总经理、湖南 湘邮科技股份有限公司独立董事。 经过自查，作为公司独立董事，本人符合《上市公 ...

2025年4月23日，公司将暂时补充流动资金的1.5亿元募集资金归还至募集资 金专项账户。 证券代码：600645 证券简称：中源协和 公告编号：2025-009 中源协和细胞基因工程股份有限公司 关于归还暂时补充流动资金的闲置募集资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 中源协和细胞基因工程股份有限公司（以下简称"公司"）于2024年4月24 日召开十一届十次董事会会议和十一届四次监事会会议，审议通过了《关于使用 闲置募集资金暂时补充流动资金的议案》，同意公司在不影响募集资金投资计划 正常进行的前提下，使用不超过1.5亿元的闲置募集资金暂时补充流动资金，使 用期限自公司董事会审议通过之日起不超过12个月。（具体内容详见公司公告： 2024-017） 截至本公告日，公司用于暂时补充流动资金的募集资金已全部归还至募集资 金专项账户，决议有效期内不存在影响募投项目实施和募集资金使用的情形。 特此公告。 中源协和细胞基因工程股份有限公司 二○二五年四月二十四日 1 ...